CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment
Novo Nordisk A/S (NYSE:NVO) announced that CVS Health Inc’s (NYSE:CVS) CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy (semaglutide) injection 2.4 mg will soon be the preferred GLP-1 medicine on its largest commercial template formularies.
This change will take effect on July 1, 2025.
“We believe in the unique benefits of Wegovy and the difference this medicine can make for patients seeking treatment,” said Dave Moore, executive vice president of U.S. Operations and president of Novo Nordisk Inc.
Independent of this formulary decision, Novo Nordisk will continue to work with CVS to identify additional ways to expand access to Wegovy for its customers.
Also Read: Novo Nordisk Wins Legal Battle To Curb Unsafe Knockoff Versions Of Ozempic, Wegovy
In February, the FDA confirmed that all doses of Wegovy were available. In March, Novo Nordisk launched NovoCare Pharmacy to provide direct-to-patient, convenient home shipments of all Wegovy dose strengths at a reduced cost of $499 per month for self-paying patients.
More recently, the Wegovy savings offer was updated, allowing eligible self-paying patients to get the $499-per-month price at their local pharmacy.
The FDA expanded the label in 2024 to include an indication for reduction of the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
On Tuesday, Novo Nordisk and Hims & Hers Health, Inc. (NYSE:HIMS) announced a long-term collaboration.
The company said that at a single, unified price starting at $599 per month, individuals may be prescribed Wegovy. The offering is available this week on the Hims & Hers platform.
This new offering builds on Hims & Hers' existing suite of weight loss solutions and provides self-pay patients with access to all dose strengths of Wegovy in a high-quality pen.
Price Action: NVO stock is down 1.78% at $65.27 at the last check Thursday
Read Next:
Photo: Shutterstock
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
English